Q2 2025. No major surprises, unless one counts the fact that the illustrative “Quarter on Quarter Performance” chart, which was included in the previous report, has been dropped from the report – perhaps it wouldn’t give a sufficiently positive picture of the development. So I compiled one myself, the result is below.
Revenue 49.1 MSEK, almost entirely product sales (approx. 16 commercially treated Idefirix patients). Sarepta’s problems are likely reflected in the fact that there are hardly any contract revenues. During the period, a directed share issue of 232 MSEK was carried out, about half of which was consumed as cash flow during the quarter. At the same time, the NovaQuest loan restructuring was agreed upon. The development of cash flow (= costs) is, in itself, a positive aspect of the report.
